Our Story

ZATA Aesthetics, Inc., is the newest venture of ZATA Pharmaceuticals.


We are established in Worcester, MA (USA). From its parent company, ZATA Aesthetics (ZAI) has inherited broad capabilities and 10+ years of expertise in the field of medical devices and aesthetic medicine. This includes evaluation, optimization, and FDA clearance of power-based medical devices. Driven by dedicated minds in development, ZATA Aesthetics is ready to support and lead the next novel commodity to the forefront of the industry.

Our Mission

The drive of ZATA Aesthetics from its conception has been to give practitioners and patients the best possible chances for long-term success through the development of effective treatments and/or devices, both independently and through partnerships in the field.


Our current focus is on the development, testing, improvement, and commercialization of the novel power-based medical (PBM) devices we help onto the market. Reimagining these singular treatments would aid the aesthetic and medical communities, as well as the patients they treat. We at ZATA Aesthetics believe there is always room for improvement and expansion in the field of PBM devices of dermatologic and aesthetic medicines.

Our Future Vision

While evaluating the wide range of therapies on the market, the ZAI team noticed that there are much broader applications for the current range of PBM. PBMs can be successfully used in combination of various medical modalities as it is listed in the innovation block below.

Our future goal is to address and reinvent both medical devices and pharmaceutical treatments by using them together for a more effective and complete result.

ZAI aims to develop these cutting-edge technologies in partnership with companies that have established sales networks. This collaboration would enable us to introduce new products or technologies to the market as soon as possible. Most of the applications we have envisioned will be patent protected.

How We Can Help

For over a decade, ZATA Pharmaceuticals, the parent company of ZATA Aesthetics, has accumulated unique experience and concepts in the fields of dermatologic and aesthetic medicines.

Proven Results

ZATA Pharmaceuticals, before forming the ZATA Aesthetics subsidiary, provided services to over a dozen international and domestic companies. Primarily, ZPI supported the valuation, optimization, and FDA clearance of over two dozen power-based medical (PBM) devices. The systems of those devices utilize lasers, radiofrequencies, plasma, and thermo-mechanics, and are familiar sciences to the employees at ZAI.

Services

ZAI provides optimization of early-stage prototypes in various models designed towards success. Studies have been conducted on in vivo, ex vivo, and in vitro scales. These studies have been catered to the unique needs of each PBM device and managed through individual designs, structured for the most direct analyses of efficacy. Managing FDA clearance of the final prototypes and novel PMBs has been big part of ZAI’s activity.
ZAI’s expanding personnel, expertise, and capabilities aim to further the optimization and clearance services provided for preclinical therapies, growing to include services for the integration of pharmaceutical treatments in use with PBM devices.

Inventions and Innovation

Focus of ZAI’s business interest will remain on introduction of broad range of inventions and innovations with partnership of interested parties, some of which are listed below.
ZAI wants to enhance the transdermal delivery of a wide range of aesthetic and pharmaceutical treatments, as the current formulations lack sufficient skin penetration. Previously FDA-approved compositions would streamline clearance-related challenges.
Here are the examples of our research interests:
  • Enhancing the transdermal delivery of a wide range of aesthetic and pharmaceutical treatments, as the current formulations lack sufficient skin penetration.
  • Focusing on previously FDA-approved compositions would streamline clearance-related challenges.
  • Using PBM devices in conjunction with pharmaceutical formulations to enhance the wound healing process.
  • Using PBM devices in conjunction with pharmaceutical formulations to improve previous methods of scar resurfacing, aiming to reduce or eliminate their appearance.
  • Reducing abdominal fat through a novel thermocycling treatment.
  • Developing solutions to combat or reverse hair loss.
  • Improving certain components of currently used devices, such as manufacturing enhanced cartridges for radio frequency micro-needling systems.
  • Creating new formulations for topical applications, aiming to enhance thermal treatment effects on the skin.

Meet the team

DAVID R. TABATADZE, PhD
President and Founder of ZATA Aesthetics, Inc.
Dr. David Tabatadze holds an MS in organic chemistry from Javakhishvili University in the Republic of Georgia, a PhD in bioorganic chemistry from the Institute of Bioorganic Chemistry in Novosibirsk, Russia, and has undergone post-doctoral training in the field of oligotherapeutics at the Worcester Foundation for Biomedical Research in Worcester, MA.
Over the last two decades, he has also gained unique experience and expertise in the field of aesthetic medicine. From 2000 to 2011, Dr. Tabatadze worked for Palomar Inc., where he served as the principal bio-scientist. His responsibilities included preclinical evaluation and optimization of light-based medical devices for the fields of aesthetic medicine and dermatology.
Since 2013, Dr. Tabatadze has led histopathological evaluations of several dozen international and domestic origin power-based devices at ZATA Pharmaceuticals, Inc, securing their FDA clearances via 510K and De Novo pathways.
In 2023, Dr. Tabatadze founded ZATA Aesthetics, Inc. (ZAI) as an independent entity from its parent company, ZATA Pharmaceuticals, Inc. This new company is fully dedicated to assisting current and future clientele in the optimization and clearance of their novel power-based medical devices.
Victor Ilyashenko, PhD
Vice President of Business Development
Dr. Victor Ilyashenko holds a Master of Science degree in Chemical Engineering from the Lomonosov Institute of Fine Chemical Technology in Moscow, as well as a Ph.D. in Physical Chemistry from the Kurnakov Institute, Academy of Sciences of the USSR. Dr. Victor Ilyashenko spent most of his R&D career at an early-stage startup company, which has now grown to become the largest manufacturer of optical fiber laser in the world; IPG Photonics. Dr. Ilyashenko led all aspects of development and patenting of related organic and analytical chemistry at IPG. After the co-founder/CEO of the company (Dr. Valentin Gapontsev,1939-2021) passed away, the upper management's business strategy shifted to focus on the manufacturing and commercialization of products Dr. Ilyashenko had already developed. This shift inspired Dr. Ilyashenko to consider new challenges and opportunities. After meeting with Dr. David Tabatadze, President of ZATA Aesthetics, Inc. (ZAI), and gaining familiarity with the ongoing and intended projects of the company, he was welcomed on board as the Vice President of Business Development. His tremendous experience and prior contributions to power- based devices will be instrumental in the further development and commercialization of ZAI's ongoing medical and aesthetic projects. At ZATA Aesthetics, Inc., under the coordination of Dr. Tabatadze, he oversees and manages all aspects of business development and establishes strategic partnerships
IVAN B. YANACHKOV, PhD
Vice President of Business Development
Dr. Ivan Yanachkov holds an MS in Organic Synthesis from the University of Chemical Technology and Metallurgy in Sofia, Bulgaria. He also has a double PhD in Organic Chemistry, earned from the University of Chemical Technology and Metallurgy in Sofia, Bulgaria, and Clark University in Worcester, MA. Additionally, he has completed post-doctoral training in the field of medicinal chemistry and pharmacology at the University of Massachusetts Medical School.
Dr. Yanachkov has notable accomplishments in the field of medicinal and analytical chemistry. He led the development of chemical methodologies that enabled the synthesis of a new generation of oligotherapeutics, and a novel class of anti-pathogen compounds.
Before joining ZATA, he worked at GLSynthesis, Inc., where he developed and patented a highly potent antiplatelet drug candidate currently in the late stages of preclinical development.